Geneva Capital Management’s Idexx Laboratories IDXX Stock Holding History

Geneva Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.2M	Sell	40,242 -2,766	-6%	-$1.55M	0.49%	59
2026 Q1	$24.2M	Buy	43,008 +1,738	+4%	+$1.11M	0.51%	58
2025 Q4	$27.9M	Sell	41,270 -697	-2%	-$475K	0.52%	60
2025 Q3	$26.8M	Sell	41,967 -2,052	-5%	-$1.25M	0.46%	65
2025 Q2	$23.6M	Buy	44,019 +1,425	+3%	+$681K	0.4%	74
2025 Q1	$17.9M	Sell	42,594 -736	-2%	-$320K	0.33%	78
2024 Q4	$17.9M	Sell	43,330 -5,890	-12%	-$2.58M	0.31%	82
2024 Q3	$24.9M	Sell	49,220 -1,148	-2%	-$558K	0.42%	77
2024 Q2	$24.5M	Sell	50,368 -4,379	-8%	-$2.2M	0.45%	73
2024 Q1	$29.6M	Sell	54,747 -1,095	-2%	-$598K	0.52%	64
2023 Q4	$31M	Sell	55,842 -1,989	-3%	-$934K	0.59%	61
2023 Q3	$25.3M	Sell	57,831 -2,034	-3%	-$1.01M	0.53%	64
2023 Q2	$30.1M	Sell	59,865 -4,041	-6%	-$1.94M	0.59%	62
2023 Q1	$32M	Sell	63,906 -830	-1%	-$397K	0.65%	61
2022 Q4	$26.4M	Sell	64,736 -5,201	-7%	-$2.02M	0.59%	62
2022 Q3	$22.8M	Sell	69,937 -1,661	-2%	-$610K	0.53%	70
2022 Q2	$25.1M	Sell	71,598 -1,206	-2%	-$492K	0.58%	65
2022 Q1	$39.8M	Sell	72,804 -3,778	-5%	-$1.99M	0.77%	55
2021 Q4	$50.4M	Sell	76,582 -2,698	-3%	-$1.69M	0.81%	51
2021 Q3	$49.3M	Sell	79,280 -4,572	-5%	-$3.07M	0.84%	50
2021 Q2	$53M	Sell	83,852 -4,207	-5%	-$2.32M	0.86%	48
2021 Q1	$43.1M	Sell	88,059 -15,345	-15%	-$7.69M	0.74%	57
2020 Q4	$51.7M	Sell	103,404 -30,910	-23%	-$13.8M	0.88%	45
2020 Q3	$52.8M	Sell	134,314 -8,112	-6%	-$3M	1.09%	35
2020 Q2	$47M	Sell	142,426 -2,951	-2%	-$854K	1.02%	39
2020 Q1	$35.2M	Buy	+145,377	New	+$37.9M	1%	42
2014 Q3	$25.1M	Sell	425,934 -103,746	-20%	-$6.56M	0.73%	59
2014 Q2	$35.4M	Sell	529,680 -31,304	-6%	-$1.99M	0.87%	56
2014 Q1	$34.1M	Buy	+560,984	New	+$33.4M	0.8%	56

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Geneva Capital Management's IDXX Position: Q2 2026 in Review

Geneva Capital Management reduced its Idexx Laboratories (IDXX) stake by 6.4% in Q2 2026, selling an estimated $1.55M and leaving 40,242 shares worth $21.2M. The position accounts for 0.49% of the portfolio, ranked #59.

Geneva Capital Management first reported a position in IDXX in Q1 2014 and has held it in 29 quarters since. The position peaked at $53M in Q2 2021. 1,300 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Geneva Capital Management held 40,242 shares of Idexx Laboratories worth $21.2M as of Q2 2026.
Geneva Capital Management sold 2,766 Idexx Laboratories shares in Q2 2026, an estimated $1.55M.
Idexx Laboratories made up 0.49% of Geneva Capital Management's portfolio in Q2 2026, its #59 holding.
Geneva Capital Management first reported a position in Idexx Laboratories in Q1 2014 and has held it in 29 quarters since.
Geneva Capital Management's Idexx Laboratories position peaked at $53M in Q2 2021.
1,300 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Geneva Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.